









Markets
/
Stocks
/
nasdaq-pgen
/

Precigen Inc

PGEN

4.160USD

-0.030-0.72%

Close 12/26, 16:00（ET）Quotes delayed by 15 min

1.47BMarket Cap

LossP/E TTM



Precigen Inc

4.160

-0.030-0.72%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

More Details of Precigen Inc Company

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Precigen Inc Info



Ticker SymbolPGEN

Company namePrecigen Inc

IPO dateAug 08, 2013

CEOSabzevari (Helen)

Number of employees143

Security typeOrdinary Share

Fiscal year-endAug 08

Address20374 Seneca Meadows Parkway

CityGERMANTOWN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code20876

Phone13015569900

Websitehttps://precigen.com/

Ticker SymbolPGEN

IPO dateAug 08, 2013

CEOSabzevari (Helen)

Company Executives of Precigen Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Helen Sabzevari, Ph.D.

President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.

3.32M

+20.22%

Mr. Fred Hassan

Independent Director

1.15M

+12.00%

Mr. Steven R. Frank

Independent Director

1.14M

+11.34%

Mr. James S. (Jim) Turley

Lead Independent Director

595.77K

+26.11%

Ms. Vinita D. Gupta

Independent Director

579.24K

+27.13%

Mr. Jeffrey B. (Jeff) Kindler, Esq.

Independent Director

346.07K

-33.50%

Ms. Nancy Howell Agee

Independent Director

217.84K

+7.39%

Mr. Phil Tennant

Chief Commercial Officer

65.03K

+10.16%

Mr. Cesar L. Alvarez

Independent Director

Mr. Donald P. Lehr

Chief Legal Officer, Corporate Secretary

Name

Name/Position

Position

Shareholding

Change

Dr. Helen Sabzevari, Ph.D.

President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.

3.32M

+20.22%

Mr. Fred Hassan

Independent Director

1.15M

+12.00%

Mr. Steven R. Frank

Independent Director

1.14M

+11.34%

Mr. James S. (Jim) Turley

Lead Independent Director

595.77K

+26.11%

Ms. Vinita D. Gupta

Independent Director

579.24K

+27.13%

Mr. Jeffrey B. (Jeff) Kindler, Esq.

Independent Director

346.07K

-33.50%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Service

781.00K

91.24%

Product

41.00K

4.79%

Other

34.00K

3.97%

Relevant data have not been disclosed by the company yet.

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Service

781.00K

91.24%

Product

41.00K

4.79%

Other

34.00K

3.97%

Shareholding Stats

Updated: Mon, Nov 17

Shareholders

Shareholder Types

Shareholders

Proportion

Third Security, LLC

35.03%

Patient Capital Management, LLC

7.48%

Merck Serono SA

5.84%

William H. Miller III Living Trust

4.91%

Tang Capital Management, LLC

3.50%

Other

43.24%

Shareholders

Proportion

Third Security, LLC

35.03%

Patient Capital Management, LLC

7.48%

Merck Serono SA

5.84%

William H. Miller III Living Trust

4.91%

Tang Capital Management, LLC

3.50%

Other

43.24%

Shareholder Types

Shareholders

Proportion

Venture Capital

35.04%

Investment Advisor

15.87%

Individual Investor

7.79%

Hedge Fund

7.73%

Investment Advisor/Hedge Fund

6.52%

Corporation

5.84%

Research Firm

1.50%

Pension Fund

0.10%

Bank and Trust

0.05%

Other

19.56%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

286

222.21M

62.96%

+17.23M

2025Q2

298

229.52M

77.76%

-784.34K

2025Q1

334

228.75M

77.50%

-12.95M

2024Q4

336

223.34M

76.44%

-15.36M

2024Q3

342

222.44M

77.88%

+21.14M

2024Q2

350

183.56M

71.33%

-22.34M

2024Q1

356

187.95M

73.95%

-17.15M

2023Q4

369

187.18M

73.43%

-12.81M

2023Q3

377

185.65M

75.06%

-11.67M

2023Q2

383

181.15M

73.32%

-8.55M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Third Security, LLC

128.72M

36.47%

+12.39M

+10.65%

Sep 17, 2025

Patient Capital Management, LLC

16.27M

4.61%

-1.10M

-6.35%

Jun 30, 2025

Merck Serono SA

20.65M

5.85%

Mar 31, 2025

William H. Miller III Living Trust

17.39M

4.93%

+17.39M

Jun 26, 2025

BlackRock Institutional Trust Company, N.A.

9.83M

2.79%

+271.44K

+2.84%

Jun 30, 2025

The Vanguard Group, Inc.

9.07M

2.57%

+274.07K

+3.12%

Jun 30, 2025

State Street Investment Management (US)

3.03M

0.86%

-9.03K

-0.30%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.75M

1.06%

+269.58K

+7.75%

Jun 30, 2025

Iridian Asset Management LLC

4.28M

1.21%

-307.15K

-6.70%

Jun 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

Inspire Small/Mid Cap ESG ETF

0.24%

ProShares Ultra Nasdaq Biotechnology

0.14%

iShares Micro-Cap ETF

0.12%

Invesco Nasdaq Biotechnology ETF

0.12%

State Street SPDR S&P Biotech ETF

0.11%

Vanguard US Momentum Factor ETF

0.1%

Direxion Daily S&P Biotech Bull 3X Shares

0.06%

iShares Biotechnology ETF

0.05%

iShares Russell 2000 Growth ETF

0.03%

ProShares UltraPro Russell2000

0.02%

Inspire Small/Mid Cap ESG ETF

Proportion0.24%

ProShares Ultra Nasdaq Biotechnology

Proportion0.14%

iShares Micro-Cap ETF

Proportion0.12%

Invesco Nasdaq Biotechnology ETF

Proportion0.12%

State Street SPDR S&P Biotech ETF

Proportion0.11%

Vanguard US Momentum Factor ETF

Proportion0.1%

Direxion Daily S&P Biotech Bull 3X Shares

Proportion0.06%

iShares Biotechnology ETF

Proportion0.05%

iShares Russell 2000 Growth ETF

Proportion0.03%

ProShares UltraPro Russell2000

Proportion0.02%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

FAQs

Who are the top five shareholders of Precigen Inc?



The top five shareholders of Precigen Inc are:
Third Security, LLC holds 128.72M shares, accounting for 36.47% of the total shares.
Patient Capital Management, LLC holds 16.27M shares, accounting for 4.61% of the total shares.
Merck Serono SA holds 20.65M shares, accounting for 5.85% of the total shares.
William H. Miller III Living Trust holds 17.39M shares, accounting for 4.93% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 9.83M shares, accounting for 2.79% of the total shares.

What are the top three shareholder types of Precigen Inc?



The top three shareholder types of Precigen Inc are:
Third Security, LLC
Patient Capital Management, LLC
Merck Serono SA

How many institutions hold shares of Precigen Inc (PGEN)?



As of 2025Q3, 286 institutions hold shares of Precigen Inc, with a combined market value of approximately 222.21M, accounting for 62.96% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -14.79%.

What is the biggest source of revenue for Precigen Inc?



In FY2025Q2, the Service business generated the highest revenue for Precigen Inc, amounting to 781.00K and accounting for 91.24% of total revenue.

KeyAI

